Somaiya Mayur Ian

Chief Financial OfficerNewAmsterdam Pharma Co N.V. (NAMS) · full profile →Form 4 · filed Jan 22, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$3.3M
Net Open-Market Flow
-$3.3M
Transactions
9
7 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 21, 2026Sell(S)24K$33.80$823K58K
Jan 21, 2026Sell(S)15K$33.25$513K83K
Jan 21, 2026Option exercise(M)40K$9.26$368K98K
Jan 20, 2026Sell(S)900$30.64$28K118K
Jan 20, 2026Option exercise(M)60K$9.26$558K119K
Jan 20, 2026Sell(S)20K$32.38$635K58K
Jan 20, 2026Sell(S)40K$31.78$1.3M78K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 21, 2026Option exercise(M)40K$0663K
Jan 20, 2026Option exercise(M)60K$0703K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-019686) within minutes of acceptance. Every field above traces to the original document. Verify it directly: